Rhinitis, Allergic, Perennial
Conditions
Keywords
allergic rhinitis, quercetin, antioxidant, anti-inflammatory
Brief summary
This study was conducted to see before and after treatment whether it provided improvement in the patient's clinical symptoms.
Detailed description
This research is the first to be conducted with preliminary research on humans.
Interventions
OTHERQuercetin
In the treatment group, standard therapy is given along with additional quercetin at different doses.
OTHERApple Extract
In the treatment group is give of Apple extract
OTHERLoratadine 10 Mg
Control Loratadine 10 mg/day
OTHERFluticasone Furoate
Control Fluticasone Furoate 27.5 mcg twice daily
Sponsors
Universitas Sebelas Maret
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Masking description
Department Biomedic and Science Universitas Sebelas Maret Surakarta Indonesia, Department Pharmacy Universitas Muhammadiyah Surakarta Indonesia, Universitas Sebelas Maret Hospital Sukoharjo Indonesia
Intervention model description
4 group study
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 - 60 years who have signed an informed consent * Diagnosed with persistent allergic rhinitis with a Skin Prick Test or Positive IgE Examination.
Exclusion criteria
* The presence of complications in the nose such as nasal septum deviation, polyps, rhinosinusitis * Have undergone specific immunotherapy for 2 years * Use of drugs that affect allergy test results: antihistamines, corticosteroids, antihypertensive drugs, and decongestants * Pregnancy and Breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Nasal Symptom Score (TNSS) | Baseline, Month 3, and Month 6 | The TNSS evaluates the severity of four nasal symptoms: nasal congestion, sneezing, nasal itching, and rhinorrhea. Each symptom is rated on a 4-point scale: 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total score is the sum of the four individual symptom scores, ranging from 0 to 12. Higher scores indicate worse symptom severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Interleukin-6 (IL-6) Levels | Baseline, Month 3, and Month 6 | Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA). |
| Malondialdehyde (MDA) Levels | Baseline, Month 3, and Month 6 | Oxidative stress marker measured using ELISA kit. |
| Nuclear Factor-Kappa Beta (NF-kB) Expression | Baseline, Month 3, and Month 6 | Transcription factor expression by ELISA assay. |
| Serum Interleukin-8 (IL-8) Levels | Baseline, Month 3, and Month 6 | Concentration of IL-6 measured using Enzyme-Linked Immunosorbent Assay (ELISA). |
| Serum TNF-alpha Levels | Baseline, Month 3, and Month 6 | Concentration of TNF-alpha measured using Enzyme-Linked Immunosorbent Assay (ELISA). |
Countries
Indonesia
Outcome results
None listed